Abbott’s Latest Blood Glucose Monitoring System Receives FDA Clearance

Abbott has announced that the U.S. Food and Drug Administration (FDA) clearance for its FreeStyle InsuLinx Blood Glucose Monitoring System. This latest addition to Abbott’s portfolio of glucose monitoring systems has been designed to help diabetic patients monitor their blood glucose levels, allowing them to more effectively manage their condition.

The FreeStyle InsuLinx Blood Glucose Monitoring System has a touch-screen interface and an automated logbook which tracks insulin doses and glucose levels. It also has several personalization features designed to improve the diabetes management experience for patients. The device is equipped with build-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers.

"The new FreeStyle InsuLinx System represents Abbott's latest advancement in delivering innovative products for people with diabetes who use insulin," said Heather L. Mason, senior vice president, Abbott Diabetes Care. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."

The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months.